Please try another search
For the three months ended 31 March 2019, Nightstar Therapeutics PLC revenues was not reported. Net loss increased 14% to $16.4M. Higher net loss reflects General and administrative - Balancing v increase from $2.2M to $8.6M (expense), Research and development - Balancing val increase of 42% to $8.2M (expense), Stock-based Compensation in SGA increase from $535K to $1.1M (expense).
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -18.56 | -13.08 | -10.86 | -11.38 |
Net Income | -16.39 | -6.82 | -7.58 | -8.1 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 169.73 | 180.01 | 114.44 | 121.19 |
Total Liabilities | 20.01 | 14.38 | 14.76 | 12.12 |
Total Equity | 149.72 | 165.64 | 99.68 | 109.07 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 0 Months | 0 Months |
Cash From Operating Activities | -11.36 | -45.63 | -28.66 | -24.16 |
Cash From Investing Activities | 77.99 | -136 | -54.76 | -69.75 |
Cash From Financing Activities | 0 | 77.16 | 0 | 0 |
Net Change in Cash | 66.73 | -101.56 | -83.37 | -87.77 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review